Skip to main content

Matthew Harrison

Analyst

Morgan Stanley

Equibles does not estimate personal net worth.

About Matthew Harrison

Matthew Harrison is recorded as Analyst at Morgan Stanley. Matthew Harrison has spoken on 2 earnings calls across 2 companies, most recently for Biogen Inc. on February 3, 2022. Those appearances were for Biogen Inc. (BIIB) and Vertex Pharmaceuticals Inc (VRTX). The companies whose calls Matthew Harrison spoke on are classified in the Healthcare sector.

Matthew Harrison on recent calls

“I was hoping you could just clarify on the TECFIDERA EU contribution to guidance and what we are going to learn this year, which may either help us understand if that revenue is at risk this year, or if you could continue to expect to see it and that could be potential upside to your current guidance?”
Analyst — Morgan Stanley, Biogen Inc. Q4 FY2021 Earnings Call ·
“One, Stuart, can you just comment on the residual patients on SYMDEKO and ORKAMBI? Is that mainly age groups which are not approved for TRIKAFTA yet? Or have you noticed any groups that are staying on that drug that may surprise you?”
Analyst — Morgan Stanley, Vertex Pharmaceuticals Inc / Ma Q2 FY2020 Earnings Call ·

Affiliation history

  • Morgan Stanley

    Analyst

    Source not stated

    Current

Company network

Recent activity